News and Press Releases

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models

Leadership Change

Paul Higham recently resigned as CEO of the company and will leave in May to pursue other opportunities. Sari Pesonen, co-founder and currently Chief Scientific Officer, will take over as CEO in early May. Matti Hautsalo commented on behalf of the Board: 'We would like to thank Paul for his service to the company over the past almost 4 years and wish him well for the future. Sari co-founded the company in 2016 and has led the scientific development of

Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma

Four cancer types now included in PeptiCRAd-1 with Pembrolizumab trial: sarcoma, melanoma, triple negative breast cancer and non-small cell lung cancer

Valo Therapeutics Announces Acquisition of Bruker Corporation’s Latest Mass Spectrometer Platform for Tumor Antigen Identification with ValoTx’s PeptiCHIP Technology

Top-of-the-Line Molecular Analytics Instrument with Transformative Sensitivity will enable Rapid Identification of Tumor Antigens

Valo Therapeutics and Texcell Announce Research Collaboration to Evaluate Immune Responses to PeptiCRAd-1 in Phase I Clinical Study

Helsinki, Finland & Evry, France, 13 June 2023 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces a collaboration with global contract research organization, Texcell, to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study. ValoTx’s PeptiCRAd-1 combines the power of a tumor-specific adenovirus (expressing immune-stimulatory molecules CD40L and OX40L) with immunogenic tumor peptides derived from NY-ESO-1 and MAGE-A3 proteins thereby generating tumor-specific, cytotoxic T-cells that will attack and kill cancer cells. The

Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology

Germany based trial of 15 patients with melanoma, triple negative breast cancer or non-small cell lung cancer

Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology

Helsinki, Finland, 16th Feb, 2023 - Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces it has been granted European patents EP3768305 and EP3768830, issued by the European Patent Office (EPO) on 7 February 2023. The patents cover the pharmaceutical composition and method of use for the treatment of cancer for ValoTx’s lead product PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus-1). These two patents cover its lead virus VALO-D102 and the peptides coating the virus

Valo Therapeutics Secures EUR 2.23 million from the European Innovation Council to Progress Innovative PeptiCHIP Technology

Helsinki, Finland, 14th February 2023: Valo Therapeutics Oy (Valo Tx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces that it has secured funding of approximately EUR 2.23 million (around USD 2.42 million) from the European Innovation Council (EIC) for a project to progress the company’s innovative PeptiCHIP technology. PeptiCHIP rapidly identifies a tumor’s antigen presentation profile to drive development of novel personalized immunotherapies. The project, which will be fully funded by the EIC with a 100%

Valo Therapeutics selects Exothera to develop large-scale oncolytic Adenovirus manufacturing

Helsinki, Finland, January 11th, 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO) specialized in gene therapy, vaccines, and oncolytic viruses, to develop a large-scale manufacturing process for clinical development of its oncolytic adenovirus, VALO-D102. ValoTx’s VALO-D102 oncolytic adenovirus is a fundamental component of the company’s proprietary PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. The platform

Nordic Life Sciences Interview: Valo Therapeutics CEO Paul Higham

Read about what we're doing in Precision Oncology News

https://www.precisiononcologynews.com/Reprint-GW22015ValoTherapeutics

Valo Therapeutics Announces Scientific Advisory Board

Helsinki, Finland, 2nd August 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced four appointments to its Scientific Advisory Board (SAB), Professor Paolo A. Ascierto, Dr Jeffery Bockman, Dr Malcolm K. Brenner, and Professor Kevin Harrington. ValoTx’s CEO, Paul Higham, said, “We are delighted to welcome our distinguished, and expert, new SAB members. They bring a wealth of scientific and clinical understanding which will be of great help in

Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies

Helsinki, Finland, 26 July 2022: Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, announces the exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s innovative PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. This is a strategically important addition for the company as it will enable the rapid identification of tumour

Valo Therapeutics Appoints Experienced Life Sciences Executive Anthony Giovinazzo to Board

Helsinki, Finland, 27 June 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of an accomplished life sciences executive. Anthony Giovinazzo will bring his considerable track record of capital raising, drug development, and company leadership in North America to the company’s Board of Directors. In addition to his general Board role, Anthony will also join the GNC and Audit Committees. ValoTx’s CEO, Paul Higham, said, “I am

Valo Therapeutics Appoints Hemanshu Shah as Chief Business Officer

Helsinki, Finland, 16 June 2022 – Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the appointment of Dr Hemanshu Shah as Chief Business Officer (CBO), based in the US. ValoTx’s CEO, Paul Higham, said, “I am delighted to welcome Dr Hemanshu Shah as our CBO. Hemanshu brings a wealth of business development experience from an impressive career spanning corporate development, strategy, and marketing roles at Transgene, Astellas, Johnson & Johnson

Valo Therapeutics Acquires University of Helsinki´s technology that capitalizes on pre-existing immunity acquired via childhood vaccination programs to potentiate the efficacy of cancer treatment

Helsinki, Finland, 6th January 2022: Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights from the University of Helsinki, Finland, for the proprietary technology which utilises pre-existing immunity (PEI) against pathogens to enhance the therapeutic efficacy of ValoTx ´s lead platform, PeptiCRAd. This innovative approach takes advantage of existing acquired immunity (generated, for example, through vaccination against pathogens) by including pathogen specific peptides into the

Valo Therapeutics Announces €11m Fundraise to Advance PeptiCRAd Immunotherapy Platform into the Clinic; Co-founder Dr Sari Pesonen, Head of R&D, promoted to CSO

Helsinki, Finland, 15 November 2021: Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced it has successfully raised Euro 11 million (around USD 12.75 million) in an oversubscribed Pre-IPO funding round. Corporate advisory firm Ironside Capital acted as lead manager for ValoTx. The Pre-IPO fund included participation from existing investors, Freeman Road, and new investors, including ASX-listed MMJ Group Holdings. The total raised to date is now over Euro 22 million